Addressing heterogeneity and drug resistance of solid tumors:

OTS-P22 is our most advanced preclinical peptide drug conjugate targeting a receptor highly expressed in many solid tumors.  We found OTS-P22 to be highly stable in human plasma in-vitro.   In addition, a single intravenous injection of 1.4 mg/kg of OTS-P22 caused a 100% tumor growth inhibition of HCC1806 TNBC model in SCID mice with the majority of mice showing complete response.  Toxicology studies showed no effect on animal weight, white blood cells or normal organs suggesting the safety of OTS-P22.  We plan to complete the IND-enabling studies of OTS-P22 for the treatment of TNBC, metastatic ovarian and endometrial cancers with the goal to start clinical trials. 

We also plan to test the efficacy of OTS-P22 as monotherapy or combination therapy on additional solid tumors including metastatic prostate, kidney, bladder and pancreatic cancers which express the target tumor-associated antigens.

We also plan to test OTS-P32, a novel peptide drug conjugate targeting a different receptor, alone or in combination with OTS-P22.

We also plan to test well designed bispecific drug conjugates  for the treatment of advanced and metastatic solid tumors.